Cargando…

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control

INTRODUCTION: Daily dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used with other orally administered antihyperglycemic agents (AHA), as combination therapy, to treat Japanese patients with type 2 diabetes. When combination therapy is indicated, use of a once-weekly (q.w.) orally administer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gantz, Ira, Okamoto, Taro, Ito, Yuka, Sato, Asako, Okuyama, Kotoba, O’Neill, Edward A., Engel, Samuel S., Lai, Eseng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544607/ https://www.ncbi.nlm.nih.gov/pubmed/28589493 http://dx.doi.org/10.1007/s13300-017-0270-7

Ejemplares similares

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes
por: Gantz, Ira, et al.
Publicado: (2017)

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
por: Kadowaki, Takashi, et al.
Publicado: (2021)

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
por: Lee, Seung-Hwan, et al.
Publicado: (2017)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
por: Gantz, Ira, et al.
Publicado: (2017)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
por: Tajima, Naoko, et al.
Publicado: (2013)

A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment
por: Chacra, Antonio, et al.
Publicado: (2017)

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
por: Seino, Yutaka, et al.
Publicado: (2021)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

The effects of Omarigliptin on promoting osteoblastic differentiation
por: Liao, Fake, et al.
Publicado: (2021)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
por: Tajima, Naoko, et al.
Publicado: (2019)

The Effect of Age and Comorbidities on the Association Between the Medicare STAR Oral Antihyperglycemic Adherence Metric and Glycemic Control
por: Nichols, Gregory A., et al.
Publicado: (2018)

Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021)

Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction
por: Lin, Shu Ning, et al.
Publicado: (2020)

Omarigliptin alleviates cognitive dysfunction in Streptozotocin-induced diabetic mouse
por: Li, Xiaoyan, et al.
Publicado: (2022)

Omarigliptin inhibits brain cell ferroptosis after intracerebral hemorrhage
por: Zhang, Yan, et al.
Publicado: (2023)

A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
por: Hauber, A. Brett, et al.
Publicado: (2015)

Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study
por: Yoshizawa, Yuta, et al.
Publicado: (2021)

Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database
por: Wang, Tongtong, et al.
Publicado: (2018)

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
por: Ayoub, Bassam M., et al.
Publicado: (2018)

Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
por: Budoff, Matthew J., et al.
Publicado: (2021)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

Omarigliptin Protects the Integrity of the Blood–Brain Barrier After Intracerebral Hemorrhage in Mice
por: Zhang, Yan, et al.
Publicado: (2023)

A Randomized Controlled Trial of an Internet-Based Mentoring Program for Type 1 Diabetes Patients with Inadequate Glycemic Control
por: Suh, Sunghwan, et al.
Publicado: (2014)

Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic Control: Delay of Insulin Therapy
por: Nichols, Gregory A., et al.
Publicado: (2007)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
por: Guzauskas, Gregory F, et al.
Publicado: (2021)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar, Chetan S, et al.
Publicado: (2013)

Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial
por: Matsushima, Yukiko, et al.
Publicado: (2016)

Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
por: McCrimmon, Rory J., et al.
Publicado: (2021)

Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes
por: Tosaki, Takahiro, et al.
Publicado: (2017)

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
por: Ferrannini, Ele, et al.
Publicado: (2010)

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
por: Fonseca, Vivian A., et al.
Publicado: (2008)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes
por: Hattori, Sachiko
Publicado: (2020)

Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes
por: Kawasaki, Eiji, et al.
Publicado: (2021)

Efficacy of pioglitazone on glycemic control and carotid intima‐media thickness in type 2 diabetes patients with inadequate insulin therapy
por: Yasunari, Eisuke, et al.
Publicado: (2011)

Glycemic Control in Chinese Patients with Type 2 Diabetes Mellitus Receiving Oral Antihyperglycemic Medication-Only or Insulin-Only Treatment: A Cross-Sectional Survey
por: Chen, Yun, et al.
Publicado: (2015)

Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial
por: Hao, Zhaohu, et al.
Publicado: (2018)

A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES”
por: Kohli-Lynch, Ciaran N, et al.
Publicado: (2021)

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
por: Hattori, Sachiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9lf91ge0fhn728p44koa8fp5e1